Oncolys Biopharma Incis A Tokyo Based Bioventure Established In Japan In March 2004Its Mission Is To Contribute To The Advancement Of Medical Science In The World Through Bringing Innovation To The Existing Treatments For Cancer And Serious Infectious Diseasesusing Its Virology Based New Drug Discovery Technologies The Company Operates In Two Business Segmentspharmaceutical Business Segment Is Engaged In The Researchdevelopmentmanufacture And Marketing Of Novel Drugsits Major Pipeline Telomelysinobp 301 An Oncolytic Adenovirus Immunotherapy Is In Clinical Development Targeting Various Types Of Solid Tumors Including Melanoma Hcc And Esophageal Canceralong With Telomelysinan Anti Hiv Drug Obp 601Censavudineand A Novel Hdac Inhibitor Obp 801 Are Also Under Development In The United Statesdiagnostics Business Segment Is Engaged In The Researchdevelopmentmanufacture And Marketing Of Ctccirculating Tumor Celldetection Adenovirus Telomescanas Well As The Provision Of Inspection Services Oncolys Was Listed On The Tokyo Stock Exchange Mothers Market In December 2014 And Has A Clinical Laboratory Center In Kobejapan And A Subsidiary In New Jerseyusa
No conferences found for this company.
| Company Name | Oncolys Biopharma Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
